11-Apr-2022 | D | Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 10.30 a.m. and concluded at 12:45 p.m. inter- alia have considered and approved the following:
1. Recommendation of the final Dividend of Rs 0.25 (2.5%) per equity share for the financial year ended March 31, 2022, subject to the approval of the shareholders at the ensuing General Meeting of the Company. | 16-Sep-2022 | |
31-May-2021 | D | Lasa Supergenerics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 31, 2021, inter alia, has recommendationof the final Dividend of Rs. 0.25 (2.5%) per equity share for the financial year ended March 31, 2021, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. | 15-Sep-2021 | |
26-Apr-2024 | BC | Mr.Ravi Shankar kabra, CFO of the company tendered his resignation vide letter dated April 25,2024 due to health reasons and other pre occupations, he will be relieved of his duties effective end of | 26-Apr-2024 | |
08-Mar-2024 | BC | Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com | 08-Mar-2024 | |
08-Mar-2024 | BC | Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com | 08-Mar-2024 | |
05-Feb-2024 | BC | Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securit | 13-Feb-2024 | |
04-Nov-2023 | BC | Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securit | 10-Nov-2023 | |
Announcement Date11-Apr-2022
Ex Dividend Date16-Sep-2022
Dividend(%)2
Announcement Date31-May-2021
Ex Dividend Date15-Sep-2021
Dividend(%)2
No Bonus has been declared by LASASUPERGENERICS
No Split has been declared by LASASUPERGENERICS
RightsNo Rights has been declared by LASASUPERGENERICS
Book Closure
26-Apr-2024 | - | Mr.Ravi Shankar kabra, CFO of the company tendered his resignation vide letter dated April 25,2024 due to health reasons and other pre occupations, he will be relieved of his duties effective end of |
08-Mar-2024 | - | Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com |
08-Mar-2024 | - | Pursuant to Regulation 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was com |
13-Feb-2024 | - | Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securit |
10-Nov-2023 | - | Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securit |